| Authors: |
Li YD; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ma MW; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hassan MM; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Hunkeler M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Teng M; Center for Drug Discovery, Department of Pathology & Immunology, and Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA., Puvar K; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Rutter JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lumpkin RJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Sandoval B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jin CY; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Schmoker AM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Cheong H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Metivier RJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Wang MY; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Xu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Byun WS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Groendyke BJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., You I; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Sigua LH; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Tavares I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA., Zou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tsai JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Park PMC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yoon H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Majewski FC; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Sperling HT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gray NS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA. nsgray01@stanford.edu., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. eric_fischer@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. eric_fischer@dfci.harvard.edu., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. benjamin_ebert@dfci.harvard.edu.; Howard Hughes Medical Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu. |
